Cinrebafusp alfa

Cinrebafusp alfa (PRS-343) is a fusion protein developed by Pieris Pharmaceuticals. Its target is HER2 (the sponsor names HER2 x 4-1BB). The sponsor states: Cinrebafusp alfa (PRS-343) is a HER2/4-1BB bispecific anticalin-antibody fusion protein that binds HER2 on tumour cells while engaging 4-1BB (CD137) to costimulate T cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer. The largest, NCT05190445, plans to enrol 80 participants with primary completion expected 2023-02-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.